Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
5.34
+0.07 (1.33%)
At close: Mar 23, 2026, 4:00 PM EDT
5.42
+0.08 (1.50%)
After-hours: Mar 23, 2026, 6:22 PM EDT
Harvard Bioscience Revenue
In the year 2025, Harvard Bioscience had annual revenue of $86.55M, down -8.06%. Harvard Bioscience had revenue of $23.74M in the quarter ending December 31, 2025, a decrease of -3.34%.
Revenue (ttm)
$86.55M
Revenue Growth
-8.06%
P/S Ratio
2.72
Revenue / Employee
$243,803
Employees
355
Market Cap
238.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 86.55M | -7.59M | -8.06% |
| Dec 31, 2024 | 94.14M | -18.12M | -16.14% |
| Dec 31, 2023 | 112.25M | -1.09M | -0.96% |
| Dec 31, 2022 | 113.34M | -5.57M | -4.68% |
| Dec 31, 2021 | 118.90M | 16.80M | 16.46% |
| Dec 31, 2020 | 102.10M | -14.08M | -12.12% |
| Dec 31, 2019 | 116.18M | -4.60M | -3.81% |
| Dec 31, 2018 | 120.77M | 43.37M | 56.02% |
| Dec 31, 2017 | 77.41M | -27.11M | -25.94% |
| Dec 31, 2016 | 104.52M | -4.14M | -3.81% |
| Dec 31, 2015 | 108.66M | 1,000.00 | - |
| Dec 31, 2014 | 108.66M | 3.49M | 3.32% |
| Dec 31, 2013 | 105.17M | -6.00M | -5.40% |
| Dec 31, 2012 | 111.17M | 2.31M | 2.12% |
| Dec 31, 2011 | 108.86M | 685.00K | 0.63% |
| Dec 31, 2010 | 108.18M | 22.41M | 26.12% |
| Dec 31, 2009 | 85.77M | -2.28M | -2.59% |
| Dec 31, 2008 | 88.05M | 4.64M | 5.57% |
| Dec 31, 2007 | 83.41M | 7.23M | 9.49% |
| Dec 31, 2006 | 76.18M | 8.75M | 12.98% |
| Dec 31, 2005 | 67.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Embecta | 1.08B |
| AngioDynamics | 307.31M |
| OraSure Technologies | 115.02M |
| Sanara MedTech | 101.88M |
| Pro-Dex | 72.10M |
| KORU Medical Systems | 41.13M |
| Utah Medical Products | 38.52M |
| Stereotaxis | 32.38M |
HBIO News
- 11 days ago - Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 17 days ago - Harvard Bioscience Announces Reverse Stock Split - GlobeNewsWire
- 20 days ago - Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum - GlobeNewsWire
- 25 days ago - Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET - GlobeNewsWire
- 5 weeks ago - Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas - GlobeNewsWire
- 7 weeks ago - Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth - GlobeNewsWire
- 3 months ago - Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package - GlobeNewsWire